[go: up one dir, main page]

IS2884B - Kínasólínafleiður - Google Patents

Kínasólínafleiður

Info

Publication number
IS2884B
IS2884B IS8714A IS8714A IS2884B IS 2884 B IS2884 B IS 2884B IS 8714 A IS8714 A IS 8714A IS 8714 A IS8714 A IS 8714A IS 2884 B IS2884 B IS 2884B
Authority
IS
Iceland
Prior art keywords
kínasólínafleiður
Prior art date
Application number
IS8714A
Other languages
English (en)
Other versions
IS8714A (is
Inventor
Nicola Murdoch Heron
Andrew Austen Mortlock
Frederic Henri Jung
Georges Rene Pasquet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8714A publication Critical patent/IS8714A/is
Publication of IS2884B publication Critical patent/IS2884B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8714A 2002-12-24 2008-02-13 Kínasólínafleiður IS2884B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (2)

Publication Number Publication Date
IS8714A IS8714A (is) 2008-02-13
IS2884B true IS2884B (is) 2014-06-15

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7948A IS2504B (is) 2002-12-24 2005-07-20 Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
IS8714A IS2884B (is) 2002-12-24 2008-02-13 Kínasólínafleiður

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS7948A IS2504B (is) 2002-12-24 2005-07-20 Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra

Country Status (29)

Country Link
US (4) US7528121B2 (is)
EP (2) EP1578755B1 (is)
JP (3) JP4422102B2 (is)
KR (1) KR101010299B1 (is)
AR (2) AR042668A1 (is)
AT (2) ATE370958T1 (is)
AU (1) AU2003290313B2 (is)
BR (1) BRPI0317717B8 (is)
CA (1) CA2511613C (is)
CL (1) CL2003002731A1 (is)
CY (2) CY1107775T1 (is)
DE (2) DE60315892T2 (is)
DK (2) DK1578755T3 (is)
ES (2) ES2290529T3 (is)
IL (2) IL169112A (is)
IS (2) IS2504B (is)
MX (1) MXPA05006918A (is)
MY (2) MY136174A (is)
NO (2) NO335193B1 (is)
NZ (1) NZ540698A (is)
PL (2) PL221490B1 (is)
PT (2) PT1578755E (is)
RU (3) RU2350611C1 (is)
SA (1) SA04240504B1 (is)
SI (2) SI1578755T1 (is)
TW (2) TWI336327B (is)
UA (1) UA83814C2 (is)
UY (1) UY28149A1 (is)
WO (1) WO2004058781A1 (is)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006260A (es) * 2001-12-24 2005-03-31 Astrazeneca Ab Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
WO2004058752A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
EP1578755B1 (en) * 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
BRPI0409427A (pt) * 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
CA2526285A1 (en) * 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2581516C (en) 2004-10-12 2013-06-11 Astrazeneca Ab Quinazoline derivatives
JP2008515961A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1809636A1 (en) * 2004-10-19 2007-07-25 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EP2013218A2 (en) * 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
EP2262796A1 (en) * 2008-03-04 2010-12-22 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
JP5502072B2 (ja) 2008-04-30 2014-05-28 ナショナル ヘルス リサーチ インスティテューツ オーロラキナーゼ阻害剤としての縮合二環式ピリミジン化合物
EP2291376A2 (en) * 2008-07-03 2011-03-09 Merck Patent GmbH Naphthyridininones as aurora kinase inhibitors
MX2011005788A (es) * 2008-12-05 2011-06-21 Arqule Inc Inhibidores raf y sus usos.
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
AU2009324489B2 (en) 2008-12-11 2015-11-12 Axcentua Pharmaceuticals Ab Crystalline forms of genistein
AU2009330727B2 (en) 2008-12-22 2016-07-28 Millennium Pharmaceuticals, Inc. Combination of Aurora kinase inhibitors and anti-CD20 antibodies
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
TWI630203B (zh) * 2013-02-21 2018-07-21 葛蘭素史克智慧財產發展有限公司 做為激酶抑制劑的喹唑啉類
PE20160930A1 (es) * 2013-09-16 2016-09-03 Astrazeneca Ab Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso.
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
CN109688818A (zh) 2016-09-08 2019-04-26 卡拉制药公司 治疗化合物的晶型及其用途
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
PL3678668T3 (pl) 2017-09-08 2024-06-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (is) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL124728A (en) 1995-12-18 2007-06-03 Sugen Inc AURORA – 1 and AURORA – 2 proteins
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
DE69925141T2 (de) * 1998-10-08 2006-04-27 Astrazeneca Ab Chinazolin derivate
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PL354323A1 (en) 1999-09-21 2004-01-12 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
ES2305081T3 (es) 2000-06-28 2008-11-01 Astrazeneca Ab Derivados de quinozolina sustituidos y su uso como inhibidores.
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
WO2002016351A1 (en) * 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Quinazoline derivatives as kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
MXPA04006260A (es) 2001-12-24 2005-03-31 Astrazeneca Ab Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
WO2004058752A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
EP1578755B1 (en) * 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
BRPI0409427A (pt) * 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo

Also Published As

Publication number Publication date
JP2007326862A (ja) 2007-12-20
UA83814C2 (ru) 2008-08-26
BR0317717A (pt) 2005-11-22
AU2003290313B2 (en) 2007-05-10
EP1578755A1 (en) 2005-09-28
PT1847539E (pt) 2009-10-06
CL2003002731A1 (es) 2005-01-07
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
EP1847539B1 (en) 2009-08-05
DK1847539T3 (da) 2009-11-09
TW200510342A (en) 2005-03-16
SI1578755T1 (sl) 2007-12-31
ES2329623T3 (es) 2009-11-27
NO20052855D0 (no) 2005-06-13
IL169112A0 (en) 2009-02-11
BRPI0317717B8 (pt) 2021-05-25
DE60315892D1 (de) 2007-10-04
US20140162984A1 (en) 2014-06-12
TWI336327B (en) 2011-01-21
US7528121B2 (en) 2009-05-05
SA04240504B1 (ar) 2008-04-01
RU2005123485A (ru) 2006-03-10
NO20052855L (no) 2005-08-03
KR101010299B1 (ko) 2011-01-25
HK1080481A1 (en) 2006-04-28
CA2511613A1 (en) 2004-07-15
DK1578755T3 (da) 2007-11-12
HK1111417A1 (en) 2008-08-08
CY1109479T1 (el) 2014-08-13
RU2357971C2 (ru) 2009-06-10
PL377680A1 (pl) 2006-02-06
NO335193B1 (no) 2014-10-20
IL185176A0 (en) 2007-12-03
ATE370958T1 (de) 2007-09-15
JP4906608B2 (ja) 2012-03-28
MY147761A (en) 2013-01-31
TWI393710B (zh) 2013-04-21
CY1107775T1 (el) 2013-06-19
US9018191B2 (en) 2015-04-28
TW201102369A (en) 2011-01-16
SA04240504A (ar) 2005-12-03
MY136174A (en) 2008-08-29
PT1578755E (pt) 2007-10-19
IS7948A (is) 2005-07-20
JP2009046514A (ja) 2009-03-05
JP4503090B2 (ja) 2010-07-14
ES2290529T3 (es) 2008-02-16
IS8714A (is) 2008-02-13
PL412704A1 (pl) 2015-10-12
NO20131444L (no) 2005-08-03
UY28149A1 (es) 2004-07-30
JP2006512418A (ja) 2006-04-13
AU2003290313A1 (en) 2004-07-22
MXPA05006918A (es) 2005-08-18
JP4422102B2 (ja) 2010-02-24
IL185176A (en) 2011-10-31
US20060116357A1 (en) 2006-06-01
US20100069412A1 (en) 2010-03-18
BRPI0317717B1 (pt) 2017-12-19
CA2511613C (en) 2012-10-02
DE60315892T2 (de) 2008-08-14
EP1578755B1 (en) 2007-08-22
PL223998B1 (pl) 2016-11-30
IS2504B (is) 2009-04-15
PL221490B1 (pl) 2016-04-29
IL169112A (en) 2010-12-30
DE60328735D1 (de) 2009-09-17
RU2007121850A (ru) 2008-12-20
US9567358B2 (en) 2017-02-14
NZ540698A (en) 2008-05-30
US8268841B2 (en) 2012-09-18
WO2004058781A1 (en) 2004-07-15
SI1847539T1 (sl) 2010-01-29
EP1847539A1 (en) 2007-10-24
ATE438644T1 (de) 2009-08-15
KR20050088333A (ko) 2005-09-05
RU2350611C1 (ru) 2009-03-27
US20150307534A1 (en) 2015-10-29
NO335446B1 (no) 2014-12-15

Similar Documents

Publication Publication Date Title
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
IS8714A (is) Kínasólínafleiður
DE50310083D1 (de) Phthalocyaninpigmentzubereitungen
ATE318817T1 (de) Aza-arylpiperazine
ATE427876T1 (de) Luftkissenboot
DE50212349D1 (de) Hirurgie
DE50301200D1 (de) Wischblatt
DE50311715D1 (de) Weltzeituhr
DE50305301D1 (de) Einspritzventil
ATE349458T1 (de) Etonogestrelester
DE50309536D1 (de) Fadenabsaugvorrichtung
DE50310481D1 (de) Röntgenstativ
ATA1572002A (de) Managementspleisskassette
DE50307971D1 (de) Gelenklager
DE50301960D1 (de) Hydrolager
DE50302660D1 (de) Stopfmachine
DE50309499D1 (de) Librierwerkzeugen
DE50301464D1 (de) Schraubensicherung
ATA4142004A (de) Trägerverbau
EP1500402A4 (en) INHIBITOR OF CELL DEATH
NO20052813D0 (no) Celecoxib-promedikament
DE50303317D1 (de) Einschub-leistungsschalter
DE50307628D1 (de) Getraenkehalter
DE50310701D1 (de) Magnetfuehrungseinrichtung